@article {7790,
	title = {High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents},
	journal = {Leukemia Research},
	volume = {34},
	year = {2010},
	note = {Cited By :10Export Date: 21 February 2017},
	month = {2010},
	pages = {399 - 402},
	abstract = {Tissue inhibitor of metalloproteinase-1 (TIMP-1) was evaluated in the pre-treatment serum of 55 newly diagnosed patients with symptomatic myeloma. TIMP-1 was elevated in 47\% of patients and correlated with lytic bone disease and increased bone resorption. Importantly, TIMP-1 correlated with ISS stage (p=0.005) and was an independent prognostic covariate for survival [HR: 1.003 (1-1.006), p=0.004] in these patients who were all treated with novel agents (bortezomib and/or IMiDs) during their disease course. Our study provides evidence that pre-treatment serum TIMP-1 is associated with advanced myeloma and suggests the further evaluation of this molecule to better determine its prognostic potential in MM. {\textcopyright} 2009 Elsevier Ltd.},
	keywords = {Bone disease, bone markers, multiple myeloma, Survival, Tissue inhibitor of metalloproteinase-1 (TIMP-1)},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-77649187602\&doi=10.1016\%2fj.leukres.2009.08.035\&partnerID=40\&md5=206d743a806a8560d74c2927fd698c12},
	author = {Terpos, E. and Dimopoulos, M.A. and Shrivastava, V. and Leitzel, K. and Christoulas, D. and Migkou, M. and Gavriatopoulou, M. and Anargyrou, K. and Hamer, P. and Kastritis, E. and Carney, W. and Lipton, A.}
}
